Search
An American national suffering from acute myeloid leukemia, a type of cancer that starts in the blood-forming cells of the bone marrow, recently received a new lease on life after successfully seeking treatment at Taipei Veterans General Hospital (TVGH) in Taiwan.
https://focustaiwan.tw/society/202009170022
今天朋友分享了一個關於「Make a Wish 願望成真基金」的Post，一位患有白血病的十七歲女孩，靜翹，設計了環保袋禮品包義賣，希望用自己的力量為兒科病房籌款並推廣器官捐贈，令患病的小朋友勇敢面對疾病！請大家踴躍支持Make a Wish，以生命延續生命！
【最後300份，請你和我們一起幫Denise 實現這動人的願望! 】
傳送門: http://bit.ly/wishofDenise
Denise: 「我希望用親手設計的禮品包籌款，推廣器官捐贈。」
17歲的Denise 患有急性骨髓白血病。在完成治療後一年，因肺排斥急需肺移植。雖有家人時刻陪伴，靜翹卻深明住院時的難耐、照顧病者的困難、以及苦等移植的焦慮。樂天的她沒有因此氣餒，反而把這一切轉化為動力，築構了一個美麗無私的願望：用親手設計的襟章、文件夾和布袋進行籌款，購買醫療器材，幫助父母照顧重病兒童，同時推廣器官捐贈，藉以燃點別人的希望。
【Last 300 packs! Please support Denise and help spread the power of a Wish-Come-True! For more details, please visit: http://bit.ly/WishofDenise_en NOW! 】
Denise, "I wish to raise funds by designing and selling gift packs and promote organ donation."
17-year-old Denise, who suffered from Acute Myeloid Leukemia, was going through an urgent lung transplant after a year of medical treatment. She experienced the emotional stress related to hospitalization, the anxiety of waiting for organ transplant and she also witnessed the difficulties experienced by caregivers of patients. Her optimism, however, drove her to create a selfless wish: she wished to design a gift pack to raise funds for the pediatric ward and promote organ donation.
<生醫新聞>Cyclacel臨床三期的急性骨髓性白血病藥物在關鍵研究中失敗
#AcuteMyeloidLeukemia #FailedTrials #ClinicalResearch #Cyclacel #Decitabine #Sapacitabine #FDA
Cyclacel Pharmaceuticals has been taught the meaning of futility. Two years after an independent data monitoring board told Cyclacel its phase 3 acute myeloid leukemia (AML) trial was destined to fail, the ever-optimistic biotech has reported its drug sapacitabine was unable to better the active control in terms of overall survival.
The top-line data confirm an outcome that looked likely from the minute independent advisers told Cyclacel the study had failed an interim futility review in December 2014. By then, the phase 3 trial had chalked up 247 of the 424 patient deaths needed to trigger the end of the study. But, with the review finding no safety issues that would force Cyclacel to shutter the study, the NJ-based biotech pushed ahead regardless.
A little more than two years later, Cyclacel has learnt sapacitabine is no better at improving overall survival in elderly patients with AML than decitabine, an Otsuka drug FDA rejected in the indication in 2012 on the basis that it also failed to outperform the control arm in its own study. Decitabine, sold under the name Dacogen as a treatment for myelodysplastic syndromes, is used off-label in elderly AML patients because of the dearth of options in this population.
When combined with the performance of sapacitabine against some secondary endpoints, the lack of options for elderly patients with AML who cannot or will not undergo chemotherapy has given Cyclacel encouragement to continue seeking a way forward for the drug.
“We plan to discuss the data with European and U.S. regulatory authorities once subgroup analyses are completed over the next few months and will report our further plans as they develop,” CEO Spiro Rombotis said in a statement.
Rombotis and the chair of the phase 3, MD Anderson’s Hagop Kantarjian M.D., picked out the data on complete remission and safety as cause for optimism. Kantarjian, a critic of FDA’s decision to reject decitabine in AML, called the improved rate of complete remission “remarkable.” Cyclacel said the safety of the two arms was similar.
While Rombotis and Kantarjian see the data as suggesting it is still too early to write off sapacitabine, investors were less optimistic. Cyclacel dropped 30% in premarket trading, adding further woes to a stock that is down 99% on the highs it hit a decade ago. The company’s market cap prior to news of the latest setback stood at $24 million.
資料來源：http://www.fiercebiotech.com/…/cyclacel-aml-drug-fails-phas…
Currently inpatient for AML* treatment. Nonetheless, good mood drove activity....or the other way around.
*Acute Myeloid Leukemia
Latest blogpost on nutrition and exercise during Cancer: www.emilylolatan.com
